Daniel Greer, PharmD, BCPP, clinical assistant professor, Rutgers Ernest Mario School of Pharmacy, discusses the use of cognitive behavioral therapy (CBT) as a first-line treatment for chronic insomnia and barriers limiting its use.
The minimal adverse effects of cognitive behavioral therapy (CBT) and its efficacy compared with medication have led to its recommendation as a first-line treatment for chronic insomnia, but access issues remain, said Daniel Greer, PharmD, BCPP, clinical assistant professor, Rutgers Ernest Mario School of Pharmacy.
Transcript
Can you speak on the emergence of CBT for chronic insomnia?
Emergence of CBT for chronic insomnia (CBT-I) goes back a little bit. So, when I look at guidelines from 2016, 2017, or even earlier guidelines than that, CBT-I is the first-line treatment for a few reasons.
One, it's been shown to be just as effective as medications are. And 2, there's a lot less side effects, and some would even say no side effects at all. Others say that for some people, their insomnia gets a little worse before it gets better, but other than that, there's no other systemic effects or side effects like there are with medications.
So, due to these reasons, CBT-I is promoted by the guidelines, the governing bodies, physicians, providers, so that's why there's been such an emergence of this type of therapy. The biggest issue really is access. We know CBT-I works, but there's not many providers specifically trained in how to administer CBT-I, so that's one of the biggest barriers: access.
Review Emphasizes Potential Infection Risks With BTK Inhibitors
November 2nd 2024Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
PAH Treatment Outcomes Similar Regardless of Diagnosis Time
November 1st 2024The study findings underscore the importance of early initiation of macitentan and tadalafil among patients who have pulmonary arterial hypertension (PAH), and represent a shift in understanding of prognosis based on diagnosis timing.
Read More